• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

SNMMI Consensus Statement on Patient Selection and Appropriate Use of Lu-PSMA-617 Radionuclide Therapy.

作者信息

Hope Thomas A, Antonarakis Emmanuel S, Bodei Lisa, Calais Jeremie, Iravani Amir, Jacene Heather, Koo Phillip J, Morgans Alicia K, Osborne Joseph R, Tagawa Scott T, Taplin Mary-Ellen, Sartor Oliver, Morris Michael J

机构信息

Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, California;

University of Minnesota Masonic Cancer Center, Minneapolis, Minnesota.

出版信息

J Nucl Med. 2023 Sep;64(9):1417-1423. doi: 10.2967/jnumed.123.265952. Epub 2023 Jun 8.

DOI:10.2967/jnumed.123.265952
PMID:37290800
Abstract
摘要

相似文献

1
SNMMI Consensus Statement on Patient Selection and Appropriate Use of Lu-PSMA-617 Radionuclide Therapy.核医学与分子影像学会（SNMMI）关于Lu-PSMA-617放射性核素治疗患者选择及合理应用的共识声明
J Nucl Med. 2023 Sep;64(9):1417-1423. doi: 10.2967/jnumed.123.265952. Epub 2023 Jun 8.
2
Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer.镥 177-PSMA-617 治疗转移性去势抵抗性前列腺癌。
N Engl J Med. 2021 Sep 16;385(12):1091-1103. doi: 10.1056/NEJMoa2107322. Epub 2021 Jun 23.
3
[Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial.[吕]Lu-PSMA-617 对比卡巴他赛用于转移性去势抵抗性前列腺癌（TheraP）患者：一项随机、开放标签、2 期试验。
Lancet. 2021 Feb 27;397(10276):797-804. doi: 10.1016/S0140-6736(21)00237-3. Epub 2021 Feb 11.
4
A step closer to the use of [Lu]Lu-PSMA-617 in metastatic hormone-sensitive prostate cancer.离在转移性激素敏感性前列腺癌中使用[镥]镥-PSMA-617又近了一步。
Lancet Oncol. 2024 Oct;25(10):1246-1247. doi: 10.1016/S1470-2045(24)00506-0.
5
Results of a Prospective Phase 2 Pilot Trial of Lu-PSMA-617 Therapy for Metastatic Castration-Resistant Prostate Cancer Including Imaging Predictors of Treatment Response and Patterns of Progression.Lu-PSMA-617 治疗转移性去势抵抗性前列腺癌的前瞻性 2 期试验结果，包括治疗反应的影像学预测因子和进展模式。
Clin Genitourin Cancer. 2019 Feb;17(1):15-22. doi: 10.1016/j.clgc.2018.09.014. Epub 2018 Sep 27.
6
A Walk with Lu-177 PSMA: How Close we Have Reached from Bench to Bedside?携镥-177 PSMA 同行：我们从基础研究到临床应用已走多远？
Cancer Invest. 2020 Sep;38(8-9):486-492. doi: 10.1080/07357907.2020.1811301. Epub 2020 Sep 14.
7
Treatment Outcome, Toxicity, and Predictive Factors for Radioligand Therapy with Lu-PSMA-I&T in Metastatic Castration-resistant Prostate Cancer.镥-PSMA-I&T 放射性配体治疗转移性去势抵抗性前列腺癌的治疗结果、毒性和预测因素。
Eur Urol. 2019 Jun;75(6):920-926. doi: 10.1016/j.eururo.2018.11.016. Epub 2018 Nov 22.
8
Combining enzalutamide and [Lu]Lu-PSMA-617 in metastatic castration-resistant prostate cancer.恩杂鲁胺与[镥]镥-PSMA-617联合用于转移性去势抵抗性前列腺癌
Lancet Oncol. 2024 May;25(5):531-533. doi: 10.1016/S1470-2045(24)00179-7. Epub 2024 Apr 12.
9
Preparation of Lu-PSMA-617 in Hospital Radiopharmacy: Convenient Formulation of a Clinical Dose Using a Single-Vial Freeze-Dried PSMA-617 Kit Developed In-House.医院放射性药物制备：使用内部开发的单瓶冻干 PSMA-617 试剂盒方便地配制临床剂量。
Biomed Res Int. 2021 Nov 20;2021:1555712. doi: 10.1155/2021/1555712. eCollection 2021.
10
Exceptional 4-year response to Lu-PSMA radioligand therapy in metastatic castration-resistant prostate cancer.镥-PSMA放射性配体疗法对转移性去势抵抗性前列腺癌产生了长达4年的卓越疗效。
Eur J Nucl Med Mol Imaging. 2019 Sep;46(10):2212-2213. doi: 10.1007/s00259-019-04410-8. Epub 2019 Jul 4.

引用本文的文献

1
PSMA PET Imaging in the Management of Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Radioligand Therapy.PSMA正电子发射断层显像在接受放射性配体治疗的转移性去势抵抗性前列腺癌患者管理中的应用
Target Oncol. 2025 May 26. doi: 10.1007/s11523-025-01151-7.
2
Peptide-based drugs in immunotherapy: current advances and future prospects.免疫疗法中基于肽的药物：当前进展与未来前景
Med Oncol. 2025 Apr 23;42(5):177. doi: 10.1007/s12032-025-02739-9.
3
Targeted radioligand therapy: physics and biology, internal dosimetry and other practical aspects during Lu/Ac treatment in neuroendocrine tumors and metastatic prostate cancer.
靶向放射性配体疗法：神经内分泌肿瘤和转移性前列腺癌中镥/锕治疗期间的物理与生物学、内照射剂量学及其他实际问题
Theranostics. 2025 Mar 18;15(10):4368-4397. doi: 10.7150/thno.107963. eCollection 2025.
4
Visceral metastases, platelet dynamics, and PSA decline: from biomarkers to better outcomes in [Lu]Lu‑PSMA‑617 therapy in metastatic castration-resistant prostate cancer.内脏转移、血小板动力学与前列腺特异性抗原下降：从生物标志物到改善转移性去势抵抗性前列腺癌[镥]镥-PSMA-617治疗的预后
Theranostics. 2025 Mar 3;15(9):3724-3732. doi: 10.7150/thno.109860. eCollection 2025.
5
FAP and PSMA Expression by Immunohistochemistry and PET Imaging in Castration-Resistant Prostate Cancer: A Translational Pilot Study.去势抵抗性前列腺癌中免疫组织化学和PET成像检测FAP和PSMA表达：一项转化性初步研究
J Nucl Med. 2024 Dec 3;65(12):1952-1958. doi: 10.2967/jnumed.124.268037.
6
Superscan Pattern on Bone Scintigraphy: A Comprehensive Review.骨闪烁显像中的超级骨显像模式：综述
Diagnostics (Basel). 2024 Oct 6;14(19):2229. doi: 10.3390/diagnostics14192229.
7
Best Patient Care Practices for Administering PSMA-Targeted Radiopharmaceutical Therapy.最佳患者护理实践用于给予 PSMA 靶向放射性药物治疗。
J Nucl Med. 2024 Nov 1;65(11):1666-1671. doi: 10.2967/jnumed.124.268363.
8
Quantitative imaging for Lu-PSMA treatment response monitoring and dosimetry.用于监测镥-PSMA治疗反应和剂量测定的定量成像。
Front Nucl Med. 2023 Dec 14;3:1291253. doi: 10.3389/fnume.2023.1291253. eCollection 2023.
9
Recommendations from the Galician Oncological Society and the Galician Society of Nuclear Medicine for the use of Lu-PSMA-617 radioligand-therapy in prostate cancer.加利西亚肿瘤学会和加利西亚核医学学会关于在前列腺癌中使用Lu-PSMA-617放射性配体疗法的建议。
Clin Transl Oncol. 2025 Apr;27(4):1383-1397. doi: 10.1007/s12094-024-03662-7. Epub 2024 Sep 12.
10
Biomarker-driven molecular imaging probes in radiotherapy.基于生物标志物的放射治疗分子影像探针。
Theranostics. 2024 Jul 2;14(10):4127-4146. doi: 10.7150/thno.97768. eCollection 2024.